|
Market Closed -
Nasdaq
01:30:00 30/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 7.870 USD | +2.81% |
|
-25.05% | -35.17% |
| 15/09 | Ocular Therapeutix, Inc. Completes Pre-NDA Meeting With FDA For AXPAXLI In Wet AMD | CI |
| 15/09 | Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4 | MT |
| Market Cap | 172.84Cr 152.53Cr 144.32Cr 130.88Cr 245.38Cr 17TCr 247.8Cr 1.73TCr 667.24Cr 8.47TCr 649.01Cr 634.88Cr 27TCr | P/E 2026 * |
-5.28x | P/E 2027 * | -5.65x |
|---|---|---|---|---|---|
| Enterprise Value | 135.04Cr 119.17Cr 112.75Cr 102.26Cr 191.71Cr 13TCr 193.6Cr 1.35TCr 521.31Cr 6.62TCr 507.07Cr 496.03Cr 21TCr | EV / Sales 2026 * |
25.5x | EV / Sales 2027 * | 16.2x |
| Free-Float |
99.07% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| OCUL | Delayed | |
CBOE
| OCUL | Real-time | |
|
Tradegate
| 0OT | Real-time | |
|
Börse Stuttgart
| 0OT | Delayed | |
|
Deutsche Boerse AG
| 0OT | Delayed | |
|
Boerse Muenchen
| 0OT | Real-time | |
|
Berne S.E.
| 0OT | End-of-day quote |
Last Transcript: Ocular Therapeutix, Inc.
| 1 day | +2.81% | ||
| 1 week | -25.05% | ||
| Current month | -24.98% | ||
| 1 month | -24.03% | ||
| 3 months | -20.51% | ||
| 6 months | +4.24% | ||
| Current year | -35.17% |
| 1 week | 7.18 |  | 9.98 |
| 1 month | 7.18 | | 11.48 |
| Current year | 6.23 | | 13.03 |
| 1 year | 6.23 | | 16.44 |
| 3 years | 2 | | 16.44 |
| 5 years | 2 | | 16.44 |
| 10 years | 2 | | 24.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pravin Dugel
CEO | Chief Executive Officer | 62 | 15/04/2024 |
Jason Robins
DFI | Director of Finance/CFO | 50 | 20/01/2026 |
Nadia Waheed
CTO | Chief Tech/Sci/R&D Officer | 49 | 20/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Charles Warden
CHM | Chairman | 57 | 01/07/2019 |
| Director/Board Member | 78 | 05/11/2012 | |
Leslie Williams
BRD | Director/Board Member | 66 | 20/03/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Sell | Chief Operating Officer | -1,099 | 0.0005% | ||
| 25/08/26 | Don | Chief Executive Officer | -1,00,184 | 0.0473% | ||
| 24/08/26 | Sell | Executive/Senior Manager | -3,035 | 0.0014% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.81% | -25.05% | -37.19% | +150.64% | 172.84Cr | |
| -0.01% | +1.24% | +63.06% | +120.55% | 1,05600Cr | |
| -1.61% | -0.60% | +47.32% | +71.79% | 64TCr | |
| -1.12% | -0.72% | +17.98% | +76.63% | 47TCr | |
| +0.19% | -3.58% | +34.74% | +41.18% | 34TCr | |
| +0.17% | +3.08% | +21.07% | +29.83% | 28TCr | |
| -0.83% | -0.64% | +10.45% | +12.79% | 25TCr | |
| +1.32% | +3.27% | +54.63% | +57.63% | 23TCr | |
| -0.61% | -0.91% | +34.33% | +101.87% | 19TCr | |
| -0.76% | -0.95% | -27.51% | -60.76% | 17TCr | |
| Average | +0.30% | -2.62% | +21.89% | +60.21% | 36.18TCr | |
| Weighted average by Cap. | +0.09% | +0.23% | +38.64% | +70.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.29Cr 4.67Cr 4.42Cr 4.01Cr 7.51Cr 507.87Cr 7.59Cr 53Cr 20Cr 259.34Cr 20Cr 19Cr 834.58Cr | 10Cr 9.04Cr 8.56Cr 7.76Cr 15Cr 983.34Cr 15Cr 102.65Cr 40Cr 502.13Cr 38Cr 38Cr 1.62TCr |
| Net income | -33Cr -30Cr -28Cr -25Cr -47Cr -3.21TCr -48Cr -334.86Cr -129.06Cr -1.64TCr -125.53Cr -122.8Cr -5.27TCr | -32Cr -29Cr -27Cr -25Cr -46Cr -3.11TCr -47Cr -324.95Cr -125.24Cr -1.59TCr -121.81Cr -119.16Cr -5.12TCr |
| Net Debt | -38Cr -33Cr -32Cr -29Cr -54Cr -3.63TCr -54Cr -378.63Cr -145.93Cr -1.85TCr -141.94Cr -138.85Cr -5.96TCr | -6.6Cr -5.82Cr -5.51Cr -5Cr -9.37Cr -633.31Cr -9.46Cr -66Cr -25Cr -323.4Cr -25Cr -24Cr -1.04TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/26/29 | $7.870 | +2.81% | 52,86,714 |
| 28/26/28 | $7.655 | -20.67% | 1,54,42,389 |
| 25/26/25 | $9.650 | -1.73% | 16,21,507 |
| 24/26/24 | $9.820 | -1.80% | 18,64,662 |
| 23/26/23 | $10.00 | -4.76% | 20,89,389 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- OCUL Stock
Select your edition
All financial news and data tailored to specific country editions
